Press Releases

The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co.

23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey database Company will host a virtual R&D Day event on January 18, 2022 SUNNYVALE, Calif., Jan.